Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6510)
All Articles published online
|
Publishing Process of This Article
|
Nov 28, 2023 (publication date) through Nov 17, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Peng WT, Jiang C, Yang FL, Zhou NQ, Chen KY, Liu JQ, Peng SF, Fu L. Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study. World J Gastroenterol 2023; 29(44): 5907-5918 [PMID: 38111506 DOI: 10.3748/wjg.v29.i44.5907] |
|
|
|
| ©2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Peng WT, Jiang C, Yang FL, Zhou NQ, Chen KY, Liu JQ, Peng SF, Fu L. Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study. World J Gastroenterol 2023; 29(44): 5907-5918 [PMID: 38111506 DOI: 10.3748/wjg.v29.i44.5907] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v29/i44/5907.htm |
| Number | Citing Articles |
| 1 |
Yongzheng Hu, Yue Zhang, Wei Jiang. Targeting hepatitis B virus-associated nephropathy: efficacy and challenges of current antiviral treatments. Clinical and Experimental Medicine 2025; 25(1) doi: 10.1007/s10238-025-01584-4
|
| 2 |
Ken Lin, Su-Wen Jiang, Ai-Rong Hu. Management of antiviral treatment for chronic hepatitis B patients with high viral load. World Chinese Journal of Digestology 2024; 32(9): 625 doi: 10.11569/wcjd.v32.i9.625
|
| 3 |
Hai-Nan Ma, Kai-Sen Cao, Yan-Miao Liu, Cheng Chen, Hang Zhang, Fu-Shan Tang. Tenofovir amibufenamide: A potential alternative for chronic hepatitis B treatment. World Journal of Gastroenterology 2025; 31(10): 102580 doi: 10.3748/wjg.v31.i10.102580
|
| 4 |
Zhi-Hao Zeng, Jin-Qing Liu, Min Zhang, Cai-Liang Qiu, Zhen-Yu Xu. Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch. World Journal of Gastroenterology 2025; 31(26): 109285 doi: 10.3748/wjg.v31.i26.109285
Abstract(201) |
Core Tip(188) |
Full Article(HTML)(1220)
|
Full Article with Cover (PDF)-2247K(49)
|
Audio-238K(11)
|
Peer-Review Report-331K(37)
|
Answering Reviewers-565K(31)
|
Supplementary Material-101K(32)
|
Full Article (PDF)-1884K(90)
|
Full Article (XML)-95K(30)
|
Times Cited (1)
|
Total Visits (2776)
|
Open
|
| 5 |
Shenglong Lin, Wanlong Huang, Ziyuan Liao, Huaxi Ma, Wenjun Wu, Minghua Lin, Defu Huang, Haibing Gao. Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-78656-0
|
| 6 |
Xinye Qiu, Yue Yin, Shibin Zhang, Wei Liu. Effectiveness and safety of tenofovir amibufenamide and tenofovir alafenamide in treating elderly patients diagnosed with decompensated hepatitis B cirrhosis: a retrospective cohort study. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1545108
|
| 7 |
Li-li Liu, Yi Feng, Chao-yi Ren, Yi Liu, Ming-hui Zhu, Guo-xiang Hao, Tian-tian Gao. A Real-World Pharmacological Assessment of Tenofovir Amibufenamide and Tenofovir Alafenamide in 48-Week Chronic Hepatitis B Treatment: Efficacy, Safety, and Cost-Effectiveness. Current Medical Science 2025; 45(5): 1138 doi: 10.1007/s11596-025-00120-5
|
| 8 |
Shuqi Yang, Yijie Lin, Huatang Zhang, Yanlan Liang, Wenjin Yuan, Xing Wang, Wenwu Lin, Wencong Hong, Zhijun Su, Dawu Zeng, Xueping Yu. Efficacy of TDF, TAF, TMF, and TDF-to-TAF switch in chronic hepatitis B: a network meta-analysis. BMC Gastroenterology 2025; 25(1) doi: 10.1186/s12876-025-04289-w
|
| 9 |
Qing Zhang, Jianhua Xu, Dan Liu, Lilin Wang, Shan Ren, Sujun Zheng, Xinyue Chen, Li Qi, Junfeng Lu. Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study. Antiviral Therapy 2024; 29(5) doi: 10.1177/13596535241284226
|
| 10 |
Ruirong Tan, Hua Hua, Siyuan Zhou, Zhimin Yang, Changming Yang, Guo Huang, Jin Zeng, Junning Zhao. Current landscape of innovative drug development and regulatory support in China. Signal Transduction and Targeted Therapy 2025; 10(1) doi: 10.1038/s41392-025-02267-y
|
| 11 |
Xinxin Rong, Guangde Yang, Yuanyuan Xu, He Chen, Xia Wang, Juanjuan Fu, Li Li, Xiucheng Pan. Efficacy and Safety of Tenofovir Amibufenamide and Tenofovir Alafenamide for First‐Time HBV‐Related Decompensated Cirrhosis. Journal of Viral Hepatitis 2025; 32(4) doi: 10.1111/jvh.14029
|
| 12 |
Chuang Jiang, Zhi-Hong Zhang, Jia-Xin Li. Current status of drug therapy for chronic hepatitis B. World Journal of Gastroenterology 2025; 31(2): 99443 doi: 10.3748/wjg.v31.i2.99443
|
| 13 |
Li-Yang Meng, Chao-Ting Yang, Jian-Feng Bao, Jin-Song Huang. Effectiveness and safety of tenofovir amibufenamide in chronic hepatitis B patients. World Journal of Gastroenterology 2024; 30(26): 3261-3263 doi: 10.3748/wjg.v30.i26.3261
|
| 14 |
Yueran Wu, Xia Li, Xiaopeng Yang, Lijun Lin, Biying Zou, Yulin Chen. Effect of tenofovir alafenamide on immune function and long-term prognosis in patients with chronic hepatitis B-related liver cirrhosis using two-dimensional ultrasound evaluation. Journal of Radiation Research and Applied Sciences 2025; 18(4): 102041 doi: 10.1016/j.jrras.2025.102041
|